T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib

Leukemia and Lymphoma

Volumn 58, Issue 7, 2017, Pages 1733-1735

  Wang, Dongmei ^a,b   Pan, Hanzhang ^a,b   Wang, Yungui ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b Key of Laboratory Hematopoietic Malignancies   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; DASATINIB; DAUNORUBICIN; IMATINIB; LEUCINE; PONATINIB; PREDNISONE; THREONINE; VINCRISTINE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CASE REPORT; CHEMOSENSITIVITY; CHROMOSOME ANALYSIS; DIZZINESS; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEVER; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LABORATORY TEST; LETTER; LEUKEMIA REMISSION; LYMPHOBLAST; MALE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; SANGER SEQUENCING; TREATMENT DURATION; YOUNG ADULT; ALLELE; BONE MARROW; CHEMISTRY; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETICS; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROTEIN DOMAIN; TREATMENT OUTCOME;

ALLELES; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; MALE; MUTATION; POINT MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PYRIDAZINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84994140702     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1251591     Document Type: Letter

References (13)

1. Faderl S, Kantarjian HM, Talpaz M, et al. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91:3995–4019.
2. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia:results of the GRAAPH-2003 study. Blood. 2007;109:1408–1413.
3. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401–412.
4. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. PACE Investigators. a phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796.
5. Gibbons DL, Pricl S, Posocco P, et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci USA. 2014;111:3550–3555.
6. Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428–442.
7. Parker WT, Yeung DT, Yeoman AL, et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016;127:1870–1880.
8. How GF, Müller MC, Lim LC., Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient. Leuk Res. 2012;36:20–21.
9. O’Hare T, Eide CA, Deininger MW., Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242–2249.
10. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow-up:sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:1126.
11. Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054–1061.
12. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110:4005–4011.
13. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117:2562–2569.